CHICAGO (EGMN) - A modified version of the standard docetaxel-cisplatin-5-fluorouracil regimen for metastatic gastroesophageal adenocarcinoma produced a higher overall survival rate and longer time-to-treatment-failure intervals with considerably less toxicity than did the parent regimen in a phase II trial, investigators from a gastric cancer consortium reported.The modified docetaxel-cisplatin-fluorouracil (mDCF) regimen entails lower drug doses that are given more frequently than in the standard...